TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06237452: VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Sponsor: Vedanta Biosciences, Inc. · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 852 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,214,596

Rescue Site Savings

+$2,129,148

Unlock Full NCT06237452 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06237452 Rescue Dossier →